New hev antigenic peptide and methods

Details New hev antigenic peptide and methods New hev antigenic peptide and methods

C - Chemistry, Metallurgy

07

K

C07K 14/08 (2006.01) A61K 39/29 (2006.01) A61K 39/385 (2006.01) C07K 7/08 (2006.01) C07K 16/10 (2006.01) G01N 33/576 (2006.01) A61K 39/00 (2006.01)

Patent

CA 2283538

A highly immunoreactive viral peptide, E2, of the hepatitis E virus (HEV) genome, derived from the carboxyl terminal end region of ORF2, is disclosed. The ORF2 peptide, expressed either as a glutathione S-transferase (GST) fusion peptide (GE2) or as the viral peptide (E2) cleaved from sepharose-bound GE2, proved to be highly reactive with sera from patients having current or past infection with HEV. A special feature of E2 is that it is a conformational antigenic determinant generated by intramolecular interactions between monomers of the peptide to form homodimers. The immunoreactivity is strictly conformational in nature and is only functional when the E2 peptide is in a dimeric form such that immunoreactivity is lost upon dissociation of the dimer. Moreover, diagnostic methods useful in detecting HEV infection and an antigen vaccine composition effective in preventing hepatitis E virus infection in which E2 is utilized are also disclosed.

Affiliated with

Also associated with

Rating

New hev antigenic peptide and methods does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with New hev antigenic peptide and methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and New hev antigenic peptide and methods will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1804197